AMRN - Amarin Corporation plc
Amarin Corporation plc
Iconic Offices, The Greenway
Block C Ardilaun Court St Stephens Green
Dublin 112-114
Ireland
353 0 166 99020
https://www.amarincorp.com
Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 365
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Aaron D. Berg | Interim CEO & Pres | 913.7k | N/A | 1963 |
| Mr. Thomas Charles Reilly | CFO, Sec. & Sr. VP | 856.49k | N/A | 1973 |
| Dr. Steven B. Ketchum Ph.D. | Pres of R&D, Exec. VP and Chief Scientific Officer | 991.19k | N/A | 1965 |
| Dr. David Keenan Ph.D. | Sr. VP of Technical Operations | N/A | N/A | N/A |
| Ms. Lisa M. DeFrancesco | Sr. VP of Corp. Affairs & Investor Relations | N/A | N/A | 1980 |
| Mr. Jordan Zwick | Sr. VP of Corp. Bus. Devel. | N/A | N/A | 1988 |
| Ms. Donna Pasek | Sr. VP of HR | N/A | N/A | N/A |
| Mr. Laurent Abuaf | Pres of Europe & Sr. VP | N/A | N/A | N/A |
| Dr. Nabil Abadir | Sr. VP, Chief Medical Officer & Head of Global Medical Affairs | N/A | N/A | N/A |
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Corporate governance
Amarin Corporation plc’s ISS governance QualityScore as of 1 May 2023 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 7; Compensation: 8.
